MedTrace Logo

Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

NCT05044169 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2021-09-14

No results posted yet for this study

Summary

The main objective is to demonstrate, from the initial episode of nephrotic syndrome (NS) in children with standard prednisolone treatment, once complete remission has occurred, that the use of Broncho-Vaxom (administration for 6 months) may reduce the risk of subsequent relapse during 12-month of follow-up.

Conditions

  • Nephrotic Syndrome in Children

Interventions

DRUG

Broncho-Vaxom

administration for 6 months after remmission

Sponsors & Collaborators

  • Fang Deng

    lead OTHER

Principal Investigators

  • Fang Deng, PhD.MD. · Anhui Provincial Children's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2023-09-30
Completion
2023-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05044169 on ClinicalTrials.gov